Advances of radiotherapy for gastric cancer

doi:10.3877/cma.j.issn.2095-3224.2016.01.03

Abstract

Abstract:

Gastric cancer is one of the most common malignancy in the world, surgery is the main treatment management of gastric cancer, but surgery alone is difficult for the radical treatment in locally advanced gastric cancer. The role of neoadjuvante and adjuvante chemotherapy in advanced gastric cancer is sure, but the role of radiotherapy or chemoradiocherapy is yet controversial.

Key words: Gastric neoplasms, Therapy, Preoperative chemoradiotherapy, Intraoperative radiation therapy, Postoperative chemoradiotherapy

Yuan Zhu. Advances of radiotherapy for gastric cancer[J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2016, 05(01): 11-15.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhjzcjbdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3224.2016.01.03

https://zhjzcjbdzzz.cma-cmc.com.cn/EN/Y2016/V05/I01/11

References 28

[1]	陈万青，张思维，曾红梅，等．中国肿瘤登记地区2010年恶性肿瘤发病和死亡分析．中国肿瘤，2014，23(1): 1-10.
[2]	Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2015. CA Cancer J Clin, 2015, 65(1): 5-29.
[3]	Paoletti X, Oba K, Burzykowski T, et al. Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA, 2010, 303(17): 1729-1737.
[4]	Zhang ZX, Gu XZ, Yin WB, et al. Randomized clinical trial on the combination of preoperative irradiation and surgery in the treatment of adenocarcinoma of gastric cardia (AGC)-report on 370 patients. Int J Radiat Oncol Biol Phys, 1998, 42(5): 929-934.
[5]	Ajani JA, Mansfield PF, Janjan N, et al. Multi-institutional trial of preoperative chemoradiotherapy in patients with potentially resectable gastric carcinoma. J Clin Oncol, 2004, 22(14): 2774-2780.
[6]	Ajani JA, Mansfield PF, Crane CH, et al. Paclitaxel-based chemoradiotherapy in localized gastric carcinoma: degree of pathologic response and not clinical parameters dictated patient outcome. J Clin Oncol, 2005, 23(6): 1237-1244.
[7]	Ajani JA, Winter K, Okawara GS, et al. Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response. J Clin Oncol, 2006, 24(24): 3953-3958.
[8]	Trip AK, Poppema BJ, van Berge Henegouwen MI, et al. Preoperative chemoradiotherapy in locally advanced gastric cancer, a phase I/II feasibility and efficacy study. Radiother Oncol, 2014, 112(2): 284-288.
[9]	Fields RC, Strong VE, Gonen M, et al. Recurrence and survival after pathologiccomplete response to preoperative therapy followed by surgery for gastric or gastrooesophageal adenocarcinoma. Br J Cancer, 2011, 104(12): 1840-1847.
[10]	Diaz-Gonzalez JA, Rodriguez J, Hernandez-Lizoain JL, et al. Patterns of response after preoperative treatment in gastric cancer. Int J Radiat Oncol Biol Phys, 2011, 80(3): 698-704.
[11]	Pepek JM, Chino JP, Willett CG, et al. Preoperative chemoradiotherapy for locally advanced gastric cancer. Radiation Oncology, 2013, 8(1): 6-13.
[12]	Kumagai K, Rouvelas I, Tsai JA, et al. Survival benefit and additional value of preoperative chemoradiotherapy in resectable gastric and gastro-oesophageal junction cancer: A direct and adjusted indirect comparison meta-analysis. Eur J Surg Oncol, 2015, 41(3): 282-294.
[13]	Leong T, Smithers M, Michael M, et al. TOPGEAR: An international randomized phase III trial of preoperative chemoradiotherapy versus preoperative chemotherapy for resectable gastric cancer (AGITG/TROG/EORTC/NCIC CTG). J Clin Oncol, 2012, 30 (15 Suppl): TPS4141.
[14]	Martinez-Monge R, Calvo A F, Azinovic I. Patterns of Failure and Long-Term Results in High-Risk Resected Gastric Cancer Treated With Postoperative Radiotherapy With or Without Intraoperative Electron Boost. J Surg Oncol, 1997, 66(1): 24-29.
[15]	Glehen O, Peyrat P, Beaujard AC, et al. Pattern of failures in gastric cancer patients with lymph node involvement treated by surgery, intraoperative and external beam radiotherapy. Radiother Oncol, 2003, 67(2): 171-175.
[16]	Calvo F, Sole C, Obregon R, et al. Intraoperative radiotherapy for the treatment of resectable locally advanced gastric adenocarcinoma: topography of locoregional recurrences and long-term outcomes. Clin Transl Oncol, 2013, 15(6): 443-449.
[17]	Fu S, Lu JJ, Zhang Q, et al. Intraoperative radiotherapy combined with adjuvant chemoradiotherapy for locally advanced gastric adenocarcinoma. Int J Radiat Oncol Biol Phys, 2008, 72(5): 1488-1494.
[18]	Debenham B, Hu K, Harrison L. Present status and future directions of intraoperative radiotherapy. Lancet Oncol, 2013, 14(11): e457-464.
[19]	Zhang Q, Tey J, Peng L, et al. Adjuvant chemoradiotherapy with or without intraoperative radiotherapy for the treatment of resectable locallyadvanced gastric adenocarcinoma. Radiother Oncol, 2012, 102(1): 51-55.
[20]	Drognitz O, Henne K, Weissenberger C, et al. Long-term results after intraoperative radiation therapy for gastric cancer. Int J Radiat Oncol Biol Phys, 2008, 70(3): 715-721.
[21]	D′Angelica M, Gonen M, Brennan MF, et al. Patterns of initial recurrence in completely resected gastric adenocarcinoma. Ann Surg, 2004, 240(5): 808-816.
[22]	Smalley SR, Benedetti JK, Haller DG, et al. Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. J Clin Oncol, 2012, 30(19): 2327-2333.
[23]	Fuchs CS, Tepper JE, Niedzwiecki D, et al. Postoperative adjuvant chemoradiation for gastric or gastroesophageal junction (GEJ) adenocarcinoma using epirubicin, cisplatin, and infusional (CI) 5-FU (ECF) before and after CI 5-FU and radiotherapy (CRT) compared with bolus 5-FU/LV before and after CRT: Intergroup trial CALGB 80101. J Clin Oncol, 2011, 29(15_suppl; abstr 4003): 256s.
[24]	Lee J, Lim do H, Kim S, et al. Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: The ARTIST trial. J Clin Oncol, 2012, 30(3): 268-273.
[25]	Park SH, Sohn TS, Lee J, et al. Phase III Trial to Compare Adjuvant Chemotherapy With Capecitabine and Cisplatin Versus Concurrent Chemoradiotherapy in Gastric Cancer: Final Report of the Adjuvant Chemoradiotherapy in Stomach Tumors Trial, Including Survival and Subset Analyses. J Clin Oncol, 2015, 33(28): 3130-3136.
[26]	Zhu WG, Xua DF, Pu J, et al. A randomized, controlled, multicenter study comparing intensity-modulated radiotherapy plus concurrent chemotherapy with chemotherapy alone in gastric cancer patients with D2 resection. Radiother Oncol, 2012, 104(3): 361-366.
[27]	Dikken JL, van Sandick JW, Maurits Swellengrebel HA, et al. Neo-adjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy for patients with resectable gastric cancer (CRITICS) . BMC Cancer, 2011, 11: 329.
[28]	Qin H L, Lin CH, Zhang XL. Evaluation of intraoperative radiotherapy for gastric carcinoma with D2 and D3 surgical resection. World J Gastroenterol, 2006, 12(43): 7033-7037.

Please choose a citation manager

Content to export